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Abstract
Mice that are incapable of expressing the small G protein Rhes have been generated and
have shown to have abnormalities in behaviors mediated by the striatum, a region in which Rhes
is highly expressed.

Moreover, conditions that result in dopamine supersensitivity and a

breakdown in D1/D2 synergism in rodents, consistently decrease rhes mRNA in striatum. Thus,
Rhes may play have relevance in dopamine signal modulation. For evaluating the role of Rhes
in anxiety, stereotypy and basal motor activity, adult male and female wild-type (WT) mice,
Rhes knockout (KO) mice, and mice heterozygous for the KO and WT alleles (Het) were tested.
There was no genotype differences in the distance traveled in the open field. However, female
KO mice showed lower anxiety than either WTs or Hets, based on the quantity of time spent in
the periphery vs. the central area of the open field (p<0.05). With respect to striatally-mediated
motor stereotypy, the mixed D1/D2 agonist apomorphine elicited a significant greater response in
male KO and Het compared to WTs (p<0.05). In previous studies of D1/D2 synergism, it has
been consistently found in rats and mice that when D2 receptors alone are stimulated, there is an
early and brief, D1 independent peak in stereotypy that disappears by 20 minutes. In the present
study, this effect was more intense in male KO mice compared to the other two genotypes during
the interval between 5 and 10 minutes (p<0.05). The current findings favor the hypothesis that
the GTP-binding protein Rhes interacts with as yet unidentified cellular proteins to buffer the
transduction of synaptic dopamine signals into intracellular responses. Decreased or loss of Rhes
therefore results in increased DA signal transduction.

Key words here: synergism, supersensitivity, stereotypy, locomotion.
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Chapter 1
Introduction

Dopamine (DA) is a catecholamine neurotransmitter and hormone formed by the
decarboxylation of L-dopa (L-dihydroxyphenylalanine). In the brain, DA serves as a major
neurotransmitter, mediating a diverse range of behaviors such as movement, attention,
motivation, and cognition (Goldman-Rakic & Selemon, 1990).

Moreover, dysfunction of

dopaminergic system underlies the symptoms of Parkinson’s disease (PD), drug addiction,
attention deficit hyperactivity disorder (ADHD) and Schizophrenia.

DA receptors are

functionally dynamic, altering their sensitivity to agonists in response to changes in the
extracellular environment.

The present research was designed to elucidate the neural

mechanisms of DA receptor plasticity, and as such, may yield important information leading to
significantly improved treatments for PD, ADHD, drug addiction, and schizophrenia.

A. Dopamine D1 and D2 receptor synergism and supersensitivity
DA receptors are G protein coupled receptors (GPCRs) that have been traditionally
classified in two different subtypes of functional receptors: D1 and D2 (Kebabian et al., 1979).
D1 type stimulates adenylyl cyclase (AC) activity and hence increases the intracellular levels of
the second messenger cyclic adenosine monophosphate (cAMP). However, D2 type inhibits the
AC and hence decreases the concentration of cAMP (Stoof & Kebabian, 1981). With respect to
behavior, different authors (Gershanik, et. al., 1983; Braun et al., 1986; LaHoste, et al., 2000)
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have pointed out the necessity of the D1 and D2 receptors synergism in the generation of the
unconditioned behaviors, like grooming, locomotor activity, exploratory activity and stereotypy.
This phenomenon is referred to as D1/D2 synergism. For example, studies in normal animals
have shown that the mixed D1/D2 agonist Apomorphine must interact with both types of
receptors for the full display of behaviors (Braun et al., 1986). In addition, when endogenous
DA is acutely depleted in rodents, the co-administration of exogenous D1 and D2 agonists is
necessary to restore the full spectrum of behaviors (Braun et al., 1986; Gershanik et al., 1983).
Furthermore, other rodent models using selective D1 or D2 antagonists (Christensen, et al., 1984;
Mailman et al., 1984) have shown that both receptors must be stimulated in order to observe
Apomorphine -induced locomotion and stereotypy. That is, antagonists acting at either D1 or D2
receptors can block behavior. The specific category or quality of the behavior generated seems
to be a function of the ratio of D1 to D2 receptor stimulation, and a function of the level of basal
D1 receptor tone. Thus, the importance of co-stimulation was not appreciated in early studies
because basal stimulation of D1 receptors by endogenous DA is sufficient to synergize with an
exogenous D2 agonist.

For understanding the D1/D2 synergism, it is necessary to clarify the neuronal distribution
of dopamine receptors in the striatum, the site where DA produces most of its behavioral effects.
The results about the distribution of DA receptors do not reach a general consensus. In fact,
some authors argue that D1 and D2 are located in the same neurons (Surmeier et al., 1992;
Surmeier et al., 1996), but others authors state they are in separate neurons (Gerfen et al., 1990;
Le Moine et al., 1991). However, the majority of research and evidence related to this aspect
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suggests that the majority of striatal neurons express only one type of dopaminergic receptor
(Gerfen et al., 1990).

Previously, LaHoste et al. (2000) have shown that the D1/D2 synergism in the striatum
does not involve actions potentials. In fact, in that study, tetrodotoxin (TTX, a Na+ channel
blocker) treatment failed to disrupt the D1/D2 synergism at striatum cellular level. Since the vast
majority of striatal neurons do not co-express D1 and D2 receptors, this paradoxical finding must
be explained by some other mechanism. In effect, some authors speculated that the synergism
arises from direct coupling of separate D1 and D2 containing neurons via gap junctions (LaHoste
et al., 2000). However, work with mutant mice has shown that neuronal gap junctions made up
of connexin-36 (Cx36) are not involved in the synergism. Rather, another unknown type of
connexin or pannexin could mediate D1/D2 synergism (Nolan et al., 2006). However, it is
important to consider possible developmental compensatory responses in mutant models that
could bias the results. Hence, a logical subsequent study could include the evaluation of the role
of Cx36 in synergism by employing mutant models that display the knockout condition in only
certain brain areas (spatial restriction) or during certain stage of development (temporal
restriction) as opposed to methods that result in brain-wide knockout, beginning at the single-cell
stage of development.

In contrast to the state of synergism that exists normally, the abolishment of the
synergism between D1 and D2 receptors can be induced under certain experimental conditions.
For instance, Arnt (1985) showed that quinpirole (a selective D2 agonist) and SKF 38393 (a
selective D1 agonist) can each independently induce classical stereotypic behaviors, after two to
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four days treatment with drugs that depletes striatal DA (reserpine). Besides, similar studies
performed with unilateral DA denervation of the striatum with the neurotoxin 6hydroxydopamine (6-OHDA) also report breakdown of the D1/D2 synergism (Ungerstedt, 1971).
In addition to the breakdown of D1/D2 synergism, chronic treatment with either reserpine or 6OHDA causes a profound increase (up to 40-fold) in behavioral sensitivity to DA agonists
(Marshall & Ungerstedt, 1977).

Since the breakdown in D1/D2 synergism is invariably

associated with supersensitivity, some authors have proposed that this supersensitivity results
from the breakdown of the D1/D2 synergism itself (LaHoste & Marshall, 1992). In effect, studies
done with genetically engineered mice suggest that depletion of DA results in the breakdown of
D1/D2 synergism and supersensitivity. For instance, a study done by Kim et al., (2000), showed
that a mutant mice deficient of DA (by inactivation of tyrosine hydroxylase gene) exhibit
receptor supersensitivity after administration of dopaminergic agonists (D1 and D2). Description
of mutant mice models of DA and motor behaviors are described in more detail in subsequent
sections.

In general, agonist stimulation of both D1 and D2 receptors is required for DA-mediated
effects under normal conditions.

However, following prolonged (> 24 hrs.) depletion of

endogenous DA there is a breakdown in D1/D2 synergism. Under this condition, independent
stimulation of either D1 or D2 receptors can elicit the full expression of DA-induced behaviors.
This breakdown of synergism is invariably associated with profound supersensitivity of both D1
and D2 receptors.
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B. Rhes protein and its interaction with dopaminergic transmission
Rhes (Ras homolog enriched in striatum) is a novel striatal specific Ras-like small G
protein very similar to Dexras-1 (Falk et al., 1999). Rhes and Dexras-1 form a distinct subfamily
of proteins within the Ras family, characterized by an extended variable domain in the carboxyl
terminal region. The pattern of expression of rhes mRNA during development is dependent on
thyroid hormone availability (Falk et al., 1999; Vargiu et al., 2001). Rhes protein is expressed in
different areas of the central nervous system, such as striatum, olfactory tubercle, hippocampus
(CA1, CA2, and CA3), cerebral cortex (parietal - layers 2, 3, 4 and 6), granular layer of
cerebellum and thalamus. However, its major level of expression is within the striatum and
olfactory tubercle (Falk et al., 1999; Vargiu et al., 2004; Harrison et al., 2006). In addition, some
authors (Harrison et al., 2006) have pointed out that rhes mRNA is particularly enriched in brain
regions that receive dopaminergic inputs, such as striatum and nucleus accumbens and that after
6-OHDA treatment, adult rats displayed decreased expression of rhes mRNA within the striatum.
Besides, rhes mRNA showed a medial-lateral gradient in caudate-putamen (CPu), which is the
main input structure of the striatum; in effect, these authors reported a higher expression in
lateral regions, a pattern similar to that of D1 receptor mRNA, and protein. The same study also
demonstrated that rhes is differentially expressed in the NAc, with the major levels of expression
in the lateral shell, followed by medial shell, and the core. Rhes is also expressed outside of the
nervous system in the thyroid and pancreas glands (Chan et al., 2002), where regulate secretion
of thyroid hormone and insulin, respectively. Furthermore, during development, the expression
of rhes is low during embryonic and early postnatal stages, but increases progressively and
become significantly detectable between postnatal days 10 and 15, and decreases during
adulthood (Falk et al., 1999; Harrison, Ruskin & LaHoste, 2006). This temporal pattern of
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expression is similar to that of thyroid hormone and suggests that thyroid hormone regulates its
expression (Bernal & Guadaño-Ferraz, 1998; Vargiu et al., 2000). In addition, rhes expression is
drastically reduced in hypothyroid rodents (Falk et al., 1999).

Recent studies (Vargiu et al., 2004) have begun to elucidate the molecular
characterization and role of Rhes in intracellular signaling pathways.

Specifically, after

farnesylation, Rhes is targeted to the plasma membrane, where it binds and activates PI3K
(phosphoinositide 3-kinase), but does not bind to Ras nor activates the ERK (extracellular
regulated kinase) pathway. Furthermore, according to Vargiu et al., (2004), Rhes has a notable
role in GPCR signaling. Rhes obstructs the stimulation of cAMP/PKA pathway mediated by the
thyroid stimulating hormone receptor and by an active form of the ß2 adrenergic receptor. In
general, there is a consensus that Rhes could directly modulate the activation of the
heterotrimeric G proteins to which GPCRs are coupled; however, the precise mechanism is not
year clear (Cismowsky et al., 1999, 2000; Graham et al., 2002). Vargiu et al., (2004), propose
three possible explanations for the mechanism of interaction between rhes and GPCR. In the
first explanation, Rhes competes with the Gαs for binding to the receptor. Rhes would therefore
inhibit receptor-mediated signal transduction by separating the receptor from the heterotrimeric
complex and blocking its activation. In the second explanation, Rhes forms a heterodimer with
Gαs when GDP is bound, preventing it from loading with GTP. In the third explanation, Rhes
performs its inhibitory effect in an indirect way, probably by an unidentified kinase.

New studies have examined the relevance of Rhes in striatal dopaminergic transmission,
specifically in the supersensitivity state of DA receptors (Harrison et al., 2006). In striatum,
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there is a relationship among the level of DA receptor sensitivity, the quantity of dopamine, and
the expression of Rhes protein. Conditions that result in breakdown of D1/D2 synergism and DA
receptor supersensitivity (i.e., DA denervation by 6-OHDA; reserpine treatment) invariably
cause a decrease in rhes mRNA levels in the striatum. In addition, the change in rhes levels is
long lasting (more than 6 months) and precisely correlated with treatments that generate receptor
supersensitivity (Harrison et al., 2006). However, rhes mRNA levels do not change significantly
under pharmacological treatments that induce numeric upregulation of striatal DA receptors
(e.g., chronic D2 antagonism), but do not cause profound supersensitivity (Harrison et al., 2006).
In summary, rhes mRNA expression diminishes under states that sustain dopamine receptor
supersensitivity and a breakdown of the D1/D2 synergism, but not under states that generate
receptor up-regulation without marked supersensitivity. These findings are consistent with those
of Vargiu and his colleagues (see above) showing that Rhes interferes with GPCR signaling.
Thus, decreased levels of Rhes would be expected to increase GPCR signaling, such as that
mediated by DA receptors.

C. Dopaminergic mutant mice: Elucidating the relationship between the
dopaminergic system and motor behavior
Different studies on motor behavior using mutant mice have confirmed the general results
obtained with pharmacological and lesion models. Specifically, knockout of D1 receptors in
mice results in reduced rearing, but conserved unconditioned behaviors like locomotion and
spontaneous alternation (El-Ghundi et al., 1999). Other D1 receptor knockout studies reported
that mice displayed deficits in motor activity in the open field test; in effect, these mice showed
reduction in path length in the first day (Smith et al., 1998). Another study done on the
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relevance of D1 in morphine response suggested that D1 is also involved in morphine’s locomotor
sensitivity; effectively, mice lacking D1 receptor didn’t show morphine’s locomotor sensitization
(Becker, A., 2001). Finally, other series of D1 deficient mice studies (Xu et al., 1994) show that
these receptors are essential in cocaine’s locomotor stimulant effects.

Studies done on D2 receptor mutant mice suggest its relevance in motor behavior. For
example, work done in D2 knockout mice (Baik et al., 1997) has demonstrated that mice display
a variety of motor deficits, such as akinesia, bradykinesia, abnormal posture, abnormal gait,
reduced locomotion, deficits in backward movements (open field test), lack of motor
coordination (rotarod test), cataleptic behavior (ring test), and marked reduction in spontaneous
movements. Some of these behaviors are very similar to those found in Parkinson disease. In
general, it can be affirmed that mutant and pharmacological models of the D2 receptor effects on
motor activity lead to the same general conclusion: D2 receptors are fundamental for motor
control (Baik et al., 1995). However, other D2 knockout studies (Kelly et al., 1998) have found
both similarities and differences with the Baik et al. study (1995); the discrepancies could be
explained by differences in genetic construct, mice’s genetic background, and procedures for
examining behaviors.

Research done in mice with a knockout of D3 receptors (a subtype of the D2 subfamily)
has suggested its importance also in motor behavior and D1/D2 synergism. For instance, D3
knockout work has reported that knockout mice exhibit hyperactivity in an exploratory test, and
increased rearing (Accili et al., 1996). Additionally, this study was consistent with previous
pharmacological studies showing increase in motor activity under D3 antagonist conditions
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(Waters et al., 1993), and decrease in motor activity with a selective D3 agonist (7-OH-DPAT;
Daly et al., 1993). In general, it can be concluded that D3 receptors exert an influence on motor
behavior that is opposite to that of D1 or D2 receptors; that is, agonist stimulation of D3 receptors
inhibits motor behavior. Moreover, D3 knockout studies (Xu et al., 1997) have also elucidated
the role of D3 receptors in D1/D2 synergism. Specifically, D3 knockout mice showed higher
levels of activity than wild type mice when both D1 and D2 receptors were stimulated either by
combinations of selective D1 and D2 class agonists or by the dopamine uptake inhibitor cocaine,
but not when either class of receptor is activated alone. This suggests that in normal mice the D3
receptor can limit the expression of motor behavior mediated by D1/D2 synergism. However, the
modulatory effects of D3 receptors occur at the system level rather than the cellular level because
electrophysiological analysis on individual neurons did not show alteration in the D1/D2
synergism (Xu et al., 1997).

Other studies knocking out the D4 receptor (another D2 subtype) have clarified its role in
motor activity (Rubinstein et al., 1997).

For instance, D4 knockout mice showed reduced

spontaneous locomotor activity and rearing; however, the mutants did better than wild type mice
in the rotarod test and showed locomotor supersensitivity to ethanol, cocaine and
methampethamine (Rubinstein et al., 1997; Kruzich et al., 2004). By contrast, some studies have
reported that D4 receptors are not necessary for the expression of behavioral sensitization in
response to amphetamine in adult mice, contradicting earlier findings (Feldpausch et al., 1998).
As a general consensus, D4 receptor knockout mice showed higher levels of dopamine synthesis
in dorsal striatum and this could explain the outperformance in rotarod test and supersensitivity
to stimulants and ethanol (Rubinstein et al., 1997).
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Finally, further mutant rodent studies have pointed out the relevance of the combined
action of D1 and D2 in motor synergism (Kobayashi et al., 2004). Simultaneous knockout of D1
and D2 receptors is lethal during the second or third week after birth (Kobayashi et al., 2004).
Prior to death, these mutant mice showed alteration of feeding and gastrointestinal function, and
severely retarded growth.

In general, it can be concluded that there are marked differences between the D1, D2, D3
and D4 mutant mice. The D2 knockout mice showed behaviors related to Parkinson dysfunction,
and decreased fertility (Baik et al., 1995). Mice lacking D1 receptor displayed reduction in brain
and body size, reduction in rearing behavior but minimally affected locomotor activity. Rodents
with disruption in D3 receptor show normal physical appearance and a sort of hyperactivity.
Mice knockout of D4 receptor displayed superior rotarod performance and supersensitivity to
stimulants and ethanol.

Because rhes is a protein found in very few areas of the central nervous system, but
highly abundant in basal ganglia, and because its levels of expression are very related to the
levels of dopamine neurotransmitter release in the nigrostriatal projections, it seems reasonable
to explore in more detail rhes protein distribution in D1 and D2 neurons of striatum and its role in
motor behavior. More specifically, the elucidation of the distribution of rhes protein in D1 and
D2 neurons under different dopamine levels (normal or depletion) in nigrostriatal system could
clarify the basic mechanisms of motor behavior at cellular and molecular levels. Besides, the

10

clarification of the effects of rhes genetic ablation in motor behavior models could also let to the
establishment of its role in normal and pathological motor behaviors.

D. Gender differences in dopaminergic modulation of motor behavior
One of the most relevant sex differences found in the dopaminergic system of rodents is
the higher overproduction and elimination of dopamine receptors in male compared to female
rodents (Andersen et al., 2002; Teicher et al., 1995). Specifically, along periadolescent period
(between 25 and 40 postnatal days), there is overproduction of dopamine receptors in striatum.
This overproduction is followed by higher pruning in males compared to females (between
postnatal days 40 and 120); however, by 120 days of age, both genders display similar density of
dopaminergic receptors (Teicher et al., 1995). This developmental gender differences in rodents
could suggests similar subjacent differences in humans.

In fact, a hypothetical similar

developmental trend in human striatum could explain the higher incidence and earlier onset of
some neuropsychiatric disorders in male. For instance, disorders associated to dopamine, like
ADHD and Tourette syndrome, are more frequent in males than females (Andersen et al., 1997).
However, studies done for clarifying the origin of this developmental difference have not found
reliable explanations; for instance, a study done by Andersen et al., (2002) report the lack of
effects of gonadal hormones on dopamine receptor density changes in both sexes. However, it
was found that increase of testosterone levels is associated with increase of binding to D1
receptor in females.

Furthermore, additional gender differences in basal ganglia dopaminergic system have
been reported during peripubertal and adult stages. For example, during the temporal period
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from 25 to 120 days, males display higher levels of D1 receptors overproduction in NAc
compared to females, and sustain it during adulthood (Andersen et al., 1997). Also, other series
of studies have described in rodent adult female striatum higher rates of dopamine release and
reuptake, and higher dopamine transporter levels (DAT) compared to males (Rivest et al., 1995;
Walker et al., 2000). Besides, other set of studies (Festa et al., 2004) have described that adult
male rats have higher rates of dopamine turnover in the caudate putamen (CPu) than female
suggesting differences in autoreceptor mediated dopaminergic activity. Moreover, other studies
have found sexual differences in adult rodent motor behaviors after cocaine administration (Chin
et al., 2002; Festa et al., 2004; Van Haaren & Meyer, 1991). In particular, female rodents
display higher motor and stereotypic activity after acute and chronic cocaine administration, and
show faster sensitivity to cocaine’s behavioral effects compared to male.

This could be

explained by findings of J.B. Becker (1999); this author reported that the effects of estrogen in
dopaminergic activity of striatum and nucleus accumbens could result in gender differences in
sensitization to psychomotor stimulants.

Additionally, according to Capper-Loup et al., (2002), the repetitive and stereotypic
behaviors generated by repeated exposure to psychostimulants like cocaine, are mediated by the
synergism of D1 and D2 receptors at the stritosome level. This author also reports that there is a
direct correlation between the degree of behavioral stereotypy and the levels of gene expression
in the striatosome, as previously proposed by LaHoste et al., (1993b), in similar line of studies.
Furthermore, after cocaine acute administration, it has been found that adult male displayed
higher reduction in the level of D1 binding sites in the CPu compared to females (Festa et al.,
2006). Moreover, some studies (Schindler & Carmona, 2002; Festa et al., 2006) have reported
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that lower doses of D1 antagonist (SCH-23390) are able to inhibit cocaine-induced activity in
adult females but not males. These findings could suggest underlying adult gender differences in
receptor desensitization or in components of intracellular signaling cascades (Festa et al., 2006).

It is important to consider that besides sex differences in dopaminergic activity and motor
behavior, there are also within female variability due to estrous cycle phase (Becker, 1999).
Specifically, in female rats, estrogen and progesterone modulate dopaminergic activity in
striatum and nucleus accumbens generating differences in response. For example, variability in
basal extracellular concentrations of striatal DA, variability in DA release induced by
amphetamine, and variability in behaviors mediated by striatal dopamine. Becker also proposed
(1999) that estrogen performs its action by direct action via G protein coupled external
membrane receptors of striatum and NAc, enhancing DA release and dopaminergic behaviors.
However, in males, estrogen does not have effect in striatal DA release and removal of testicular
hormones does not have an effect.

E. Anxiety
In general, research agrees that anxiety is a multidimensional and intrincated disorder
from molecular to behavioral levels (Clement & Chapouthier, 1998; Gershenfeld & Paul, 1997;
Turri et al., 2001). Anxiety is a reaction to a possible hazard. Sometimes there is confusion
about the terms anxiety and fear. The distinction between these terms is that anxiety is related to
a potential hazard (e.g., the trace of a predator), but fear is related to a real risk (e.g., facing of
predator) (Holmes, 2003).
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F. Open field test as measurement of anxiety
This technique was originally designed by Hall (1934) for the study of emotions in rats.
The test is performed by placing a rodent in an unfamiliar environment difficult to escape. In
effect, some authors consider that the anxiety behavior in the open field is elicited by two main
factors: the condition of being isolated in the arena (previously the mouse has been in a group
inside a cage) and agoraphobia (the mouse face a new and larger environment). There is
variation in the setting of the test across researchers, depending on the arena shape (square,
circular, rectangular), lighting conditions, and the presence of items (columns; Takahasi et al.,
1989).

The open field is a relative simple and usually employed behavioral technique for
measuring anxiety (Archer, 1973; Walsh & Cummins, 1976; Lipkind et al., 2004); moreover, it
is characterized by highly predictive validity (Holmes, 2003). Some experts in the field, like
Crawley, J. N. (1999), consider that the open field test is a very general index of anxiety, but for
more detailed anxiety behaviors, other tests might be employed. In the evaluation of anxiety in
mutant mice, it is important to have an adequate control of the environment, maternal behavior
and rearing conditions; all of these factor could affect anxiety behavior (Bale, et. al., 2002;
Holmes, 2003). Based on this, in the present study all mice (knockout, heterozygous and
control) were raised together in littermate groups. Furthermore, another factor to be considered
during anxiety evaluation is the order of the tests. Some authors (Holmes, 2003) recommend the
setting of anxiety type of tests as the first ones in the battery.

In the present study this

recommendation was followed. Another factor to be considered in the evaluation of the anxiety
in open field test is the level of locomotor activity. In effect, locomotion and anxiety interact to
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produce behavior. For instance, reduction in the levels of anxiety could be a false positive result
because motor deficits.

For addressing this point, the open field test was performed on

consecutive days (5 days); in this way, both aspects anxiety and locomotion could be more easily
evaluated controlling each other.

The open field test provides 2 basic measurements: the total distance traveled, and an
index of animal’s tendency to avoid arena center. The first one is related to the basic level of
general activity, and the second one is associated to the levels of anxiety. The total distance in
the open field as a measurement of locomotion has been previously employed in studies on Rhes
mutant mice (Spano et al., 2004), other mice strain (Calamandrei et al., 2000) and rats (Cools et
al., 1990). The avoidance of the arena center as an index of anxiety has been proved by diverse
genetic and neuropharmacological works (Clement et al., 1997; Gershenfeld & Paul, 1997).
Authors like Lipkind et al. (2004) point out that there is variability in the exact definition of
center across studies; in effect, there are values references in the range of 5 to 20 cm from the
wall. In the present study, for the definition of the center, it was employed a logical approach:
the total area of the arena was divided in half by a geometrically centered rectangle (with sides
parallel to the arena limits). In this form, the total area of the arena is divided into 2 equal parts
(center and outside) with the same probability of being occupied.

G. Logistic of the study
Alterations in DA receptor sensitivity may be causal to the pathological state of
schizophrenia. Individual differences in sensitivity may also underlie the propensity to develop
ADHD or to become susceptible to drug addiction. In addition, DA receptor supersensitivity

15

may be the cause of the “on-off” syndrome in the late stages of PD, a syndrome that necessitates
discontinuation of drug therapy, thereby hastening the patient’s death. Yet the mechanisms for
changes in DA receptor sensitivity remain elusive (LaHoste & Marshall, 1992). By comparing
gene expression in supersensitive and normosensitive tissue, our laboratory identified a fragment
of a novel gene that was later determined to be rhes. These original and subsequent findings
have confirmed that reduced rhes expression is invariably associated with DA receptor
supersensitivity. Since rhes is a novel gene, however, the pharmacological tools necessary to test
for a causal role of rhes in this phenomenon are as yet unavailable. By studying mice that have
been genetically engineered to be deficient in Rhes production, the research proposed here would
test the hypothesis that Rhes levels determine the sensitivity of DA receptors in a causal manner.
The results might yield important information leading to significantly improved treatments for
PD, ADHD, drug addiction, and schizophrenia.
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Chapter 2
Methods

A. Subjects
Rhes knockout breeder mice were donated by Dr. Daniela Spano (Stazione Zoologica
Anton Dohrn, Naples, Italy). Briefly, knockout mouse were originally generated by homologous
recombination in embryonic stem cells of mouse strain 129, which were then implanted into
cultured blastocysts of mouse strain C57BL/6 (Spano et al., 2004). Chimeric blastocysts were
then implanted into pseudopregnant C57BL/6 mice. A colony of Rhes knockout mice was
generated by interbreeding heterozygous breeder mice, thereby yielding three distinct genotypes:
(1) mice with two normal rhes alleles (“wild-type;” rhes+/+), (2) mice with two knockout alleles
(homozygous knockouts; rhes–/–), and (3) mice with one normal and one knockout allele
(heterozygotes; rhes+/–).

Adult male and female mice weighting around 15-30 g were used in the experiments.
Three genotypes were used: wild type, knockout, and heterozygous. The total of mice employed
per gender were: 26 females in the open field (n ≥ 8, per genotype group), 24 females in the
stereotypy test (n ≥ 7, per genotype group), 32 male in the open field (n ≥ 9, per genotype
group), and 35 male in the stereotypy test (n ≥ 11, per genotype group). The mice were kept in
same-sex cages, in groups, with free access to food and water. Artificial lighting was provided
from 07:00 to 19:00h. Behavioral testing was begun when mice were ≥ 6 weeks of age. All
mice were maintained and used in accordance with the guidelines for animal care and
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experimentation established by the National Institutes of Health and the University of New
Orleans Institutional Animal Care and Use Committee. Animals employed in these experiments
were bred in the Department of Psychology of the University of New Orleans.

B. Genotyping
On postnatal day 21, mice were weaned. Genotyping was performed by using genomic
DNA (Deoxyribonucleic Acid) purified from tail biopsies. Mice were deeply anesthetized with
intraperitoneal (i.p.) injection of tribromoethanol (100-150 mg/10g body weight). Tail biopsies
were digested overnight at 55°C in proteinase K. After centrifugation, high molecular weight
genomic DNA was precipitated from the supernatant by addition of isopropanol. The resulting
pellet was washed with 70% ethanol, and resuspended in Tris-EDTA.

Later, DNA was

amplified by polymerase chain reaction (PCR) in a buffer solution containing: Mg2+ (3.0mM),
deoxynucleotide triphosphates (400 µM), and rhes-specific 5’ and 3’ primers (1 µM each).
Genomic DNA (1-3 µg) and Taq polymerase (0.6-1.0 U) were added to 28µl of this solution and
placed in a thermal cycler for 30 cycles of PCR. Amplification products of different molecular
weights (i.e., WT vs. KO alleles) were separated by electrophoresis in 1% agarose gel and
visualized with ethidium bromide staining.

C. Behavioral Tests
i. Open field test
Spano et al. (2004) reported that rhes-KO mice were less active than WT during the first
5 minutes of a 15-minute open field test. However, this conclusion was reached following
significant post hoc tests, after a non-significant main effect (P < 0.08), and the brevity of the test
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did not allow for the assessment of basal locomotor activity (see below). To determine whether
the presence or absence of rhes plays a role in open field activity, we placed mice in an open
field arena (43.2 cm long by 33 cm wide by 32 cm high) for 30 min., during which time multiple
measures of behavior were recorded by a digital video camera. The video signal was sent
directly to a computerized behavior analysis system (SMART). Data were collected into six 5min. time sampling bins. The open field test of anxiety has been used since 1934 (Hall, 1934),
and its construct validity has been well verified (see, e.g.., Holmes, 2003 and Introduction).

In order to test for differences in locomotor behavior that are independent of anxiety (see
Introduction), open field testing was performed on 5 successive days. One to two weeks later,
the same mice were tested for response to drug treatment (described below).

ii. Stereotypy indexes - Motor behavior following dopamine agonist stimulation
ii a. Drug treatments
For investigating D1/D2 synergism, mice received drug treatments that resulted in agonist
stimulation of D1 receptors, D2 receptors, D1 and D2 receptors, or no stimulation of receptors
(Table 1). Each mouse received each of the 4 drug treatments (A-D) once in counterbalanced
order in a Latin square design (Table 2). Drug treatments were separated by 72–96 h intervals.
All genotypes (WT, KO, and Het) were tested. All drugs were obtained from Sigma.

DA receptors were activated by the mixed D1/D2 agonist apomorphine (3.0 mg/kg, i.p.).
Individual receptor subtypes were stimulated by preceding (by 30 minutes) the apomorphine
injection with a selective antagonist.

Thus, D1 receptors were stimulated by apomorphine
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preceded by the selective D2 antagonist eticlopride (0.3 mg/kg, i.p.); D2 receptors were
stimulated by apomorphine preceded by the selective D1 antagonist SCH 23390 (0.1 mg/kg, i.p.).
In the combined D1/D2 stimulation group, apomorphine injection was preceded by saline. In the
group with no exogenous receptor stimulation, mice received two saline injections separated by
30 minutes.

Table 1. Pharmacological Treatments

Receptor(s)
stimulated

Pre-treatment
(t = -30 min.)

Agonist treatment
(t = 0 min.)

None

Saline

Saline

D1

Eticlopride

Apomorphine

D2

SCH 23390

Apomorphine

D1+D2

Saline

Apomorphine

Table 2. Counterbalanced Order of Treatments

Order

Sequence

n per Genotype

I

ABCD

3

II

BCDA

3

III

CDAB

3

IV

DABC

3
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ii b. Behavioral assay of D1/D2 synergism
Unconditioned motor behaviors were analyzed after each of the drug treatments. Each
mouse was placed in a plastic cylinder (measuring 22 cm high, 10.2 cm diameter) with a thin
layer of wood chip bedding on the bottom for 30 minutes prior to drug treatment, in order to
become familiar with its novel surroundings. Behavior was recorded with a Sony digital video
camera. Following the habituation period, mice received the pre-treatment injection (antagonist
or saline) and then were returned to the cylinder for 30 minutes; then, they received the agonist
(or control) injection and were returned to the cylinder for one hour. Experimenter-based
scoring rather than automated procedures were used due to the limitations of automation for
motor assessment in genetically-engineered mice (Clifford et al., 2000; Clifford et al., 2001).
Motor behaviors were scored for 30 seconds every 5 minutes beginning and continuing 60
minutes after the second drug is administered.

This scoring method has been previously

employed in other mutant mice studies (Nolan et al., 2007) and consists of a stereotypy scale of 0
- 5 (modified for mice from LaHoste & Marshall, 1992). This scoring method is based on an
original stereotypy scale used in rats (LaHoste et al., 1992; LaHoste et al., 1993a). The validity
of this scale to measure increasing levels of motor stereotypy was verified initially by carefully
observing the different behaviors that emerge, a) with time as brain levels of agonist increases,
and b) with increasing doses of agonist (LaHoste, G.J., personal communication).
stereotypy scale is an ordinal scale of measurement:

Stereotypy Rating Scale:
0 = still
1 = grooming or normal exploration
2 = discontinuous unfocused stereotypy
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This

(e.g. brief episodes of strong sniffing)
3 = continuous unfocused stereotypy behavior
(i.e. stereotypy directed to multiple objects and/or surfaces)
4 = continuous focused sniffing
(i.e., sniffing of one object or surface)
5 = continuous focused oral stereotypy
(i.e., licking/chewing of one object or surface)

For verification of the accuracy of the behavior scores, preliminary inter-rater reliability
analysis was performed.

This showed that both raters had significant similarity in the

assignation of scores to mice behaviors (r = 0.962, p < 0.01).

D. Determination of the estrous cycle phases of mice
For the determination of the estrous cycle phases of the female mice, it was followed the
method described by Marcondes et al., (2002). Sample of smear were collected from the female
with the aid of plastic transfer pipets, containing 10uL of normal saline (Sodium Cloride 0.9%);
the tip was inserted superficially in the female’s vagina, and the smear sample were placed in
microscopic slides. For every female, a different pipet was used. Subsequently, the samples
collected were observed under light microscope with condenser lens removed, with 10x and 40x
objective len. The criteria to determinate every phase was based in the proportion of the 3 types
of cells that were identified: epithelial cells, leukocytes and cornified (Long & Evans, 1992;
Mandl, 1951).

Specifically, a proestrus phase is characterized by abundance of nucleated

epithelial cells. The estrous phase is distinguished by clear, amorphous and enucleated cornified
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cells. Moreover, a diestrus phase is characterized by majority of leukocytes cells in the smear.
The metestrus is differentiated by an approximated equal ratio of the previous mentioned cells.

E. Statistical Analysis
Statistical data were analyzed separately for each gender.

For evaluating possible

variability between genotypic female groups due to estrous cycle, ANCOVA and ANOVA were
performed. Data from the open field sessions were analyzed by a 3 x 6 x 5 (Genotype by Time
by Day) mixed design analysis of variance (ANOVA) with Genotype (WT vs. Het vs. KO) being
a between-subjects variable and Time (0, 5, 10, 15, 20, 25, 30 min.) and Day (1-5) being
repeated measures.

In all analyses performed, “p-value” of p<0.05 was established as the

criterion for statistical significance.

A 3 x 4 x 13 (Genotype by Drug Treatment by Time) mixed design ANOVA was
conducted on stereotypy scores to determine if there were significant differences in the profiles
of behavioral motor behavior across the different groups, across time periods and across drug
treatments. Genotype (WT vs. Het vs. KO) was a between-subjects variable; Drug Treatment
(D1 vs. D2 vs. D1 + D2 vs. saline) and Time (0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 and 60
min.) were repeated measures variables. Significant main effects were analyzed post hoc by
Fischer LSD. For all the statistical analysis performed in this dissertation, a value of “p < 0.05”
was established as a criterion of statistical significance.
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F. Anticipated Results and Interpretation
i. Hypothesis 1
There will be an inverse relationship between the levels of Rhes protein in basal ganglia,
and spontaneous locomotor and exploratory activity.

In operationally defined terms,

heterozygous and/or knockout mice of either gender will, on average, travel significant longer
distances in the open field compared to wild type mice.

The rationale for this hypothesis is that if Rhes normally buffers (inhibits) DA signal
transduction via DA receptors, reduction of this protein in KO mice should result in increased
receptor sensitivity. If this hypothesis is correct, then the mouse model proposed here would be
unique in that DA receptor supersensitivity would occur in the presence of endogenous DA.
This would express itself in the form of genotypic differences in locomotor behavior in the open
field, a behavior that is mediated by DA acting in the ventral striatum. Evidence supporting this
hypothesis would be significantly increased locomotor activity in rhes KO mice (rhes –/–)
relative to controls (rhes+/+). Activity levels in Hets (rhes+/–) should be intermediate between
those of KO and WT mice. Since there is no a priori reason to suspect that Rhes levels affect
anxiety, these genotype differences might only be observed after initial exposure to the test
apparatus (when anxiety effects on activity have habituated). If the hypothesis was supported,
rhes KO mice would represent a unique and highly valuable model of schizophrenia. The mice
could subsequently be tested on abnormal social behavior, working memory and attentional
processes, among others, effects that are commonly observed in patients with this disorder.
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ii. Hypothesis 2
While WT mice will show normal D1/D2 synergism, rhes KO mice will exhibit D1/D2
independence. In operationally defined terms, WT mice will exhibit motor stereotypy only when
given apomorphine with no prior antagonist, whereas KO mice will show full motor stereotypy
whenever given apomorphine, even if it is preceeded by an antagonist injection. Het mice will
show intermediate levels of stereotypy to those of WT and KO mice.

Specifically, full

stereotypy would be elicited from KO mice by selective stimulation of D1 or D2 receptors alone,
a qualitatively different response from that of controls. Heterozygous might show a partial
breakdown in D1/D2 synergism (LaHoste et al., 1993). All genotypes would display stereotypy
upon combined stimulation of D1 and D2 receptors, but because of receptor supersensitivity, KOs
would have significantly higher ratings than WTs, with Hets again showing intermediate levels.
Such results would be consistent with our previous findings, that a breakdown in D1/D2
synergism and receptor supersensitivity are associated with decreased levels of rhes mRNA in
striatum. However, results of this nature would add a major new piece of information to our
understanding of the involvement of Rhes in dopaminergic signal transduction in that it would
indicate a causal role for this protein in DA receptor plasticity.
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Chapter 3
Results

A. Hypothesis 1
There is a direct inverse relationship between the levels of Rhes protein in basal ganglia,
and spontaneous locomotor and exploratory activity.

For having a more clear control of the possible effects of gender differences, statistical
analysis was split by gender. With respect to spontaneous locomotion in the open field, there
were no difference among KO, Het and WT mice, for both genders. Nevertheless, female (but
not male) KO mice spent significantly less time in the periphery of the open field, indicative of
lower anxiety. These conclusions are supported by statistical analysis (see next).

In female mice, there were no differences in the total distance traveled per day, among
the genotypic (WT, KO and Het) groups (Table 3), (Effect of Genotype F (2,23) = 0.296,
p=0.747; Effect of Days F (4,92) = 0.331, p=0.804; Effect of Days X Genotype F (8,92) = 1.424,
p=0.218).

Similarly, there were no differences in the daily distance traveled among male

genotypic groups (Table 3), (Effect of Genotype F (2, 29) = 0.166, p=0.848; Effect of Days F
(4,116) = 8.083, p=0.000; Effect of Days X Genotype F (8,116) = 1.098, p=0.370). Furthermore,
ANOVA of the distance traveled per time intervals (6 intervals of 5 minutes, averaged across all
the 5 days) in females (Table 3), showed an expected effect of Time (due to habituation).
However, there were no differences in the distance traveled per time interval, among female
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genotypic groups, nor was there a significant Time X Genotype interaction, (Effect of Genotype
F (2,23) = 0.410, p=0.668; Effect of Time F (5,115) = 29.927, p=0.000; Effect of Time X
Genotype F (10,115) = 0.687, p=0.678). The same results were obtained for the male groups
(Table 3), (Effect of Genotype F (2,29) = 0.110, p=0.896; Effect of Time F (5,145) = 50.616,
p=0.000; Effect of Time X Genotype F (10,145) = 2.088, p=0.056).

Amount of time spent in the periphery vs. the center of the open field was used as an
index of anxiety (see Introduction). ANOVA on these data revealed significant differences in
female but not in male mice. In particular, female KO mice showed a lower level of anxiety
compared to WT mice (Fischer LSD post hoc test, p=0.010), but there were no differences
between WT and Het mice (Figure 1), (Effect of Genotype F (2,23) = 4.068, p=0.031; Effect of
Days X Genotype F (2,23) = 0.220, p=0.804; Effect of Days F (1,23) = 0.269, p=0609). By
contrast, male genotypic groups did not differ in the levels of anxiety (Figure 2), (Effect of
Genotype F (2,29) = 0.618, p=0.546; Effect of Days X Genotype F (2,29) = 0.420, p=0.661;
Effect of Days F (1,29) = 1.718, p=0.200).

For evaluating the possible variability in female groups on locomotion, because the
estrous cycle, ANCOVA was performed to compare differences in the distance traveled in the
open field across estrous cycle (covariates: genotype, day of test, anxiety). There were no
differences in the distance traveled as a function of estrous cycle’s state (F (3,120) = 1.075,
p=0.363). Moreover, for assessing the potential variability in female groups on anxiety related to
estrous cycle, ANCOVA was performed to analyze differences in the levels of anxiety in the
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open field across estrous cycle (covariates: genotype and day). It was found no differences
because estrous cycle (F (3, 49) = 1.837, p=0.153).

B. Hypothesis 2
While WT mice will show normal D1/D2 synergism, rhes KO mice will exhibit D1/D2
independence.

For having a more clear control of the possible effects of gender differences, statistical
analysis was split by gender.

As expected, stereotypy was not observed following saline administration.

Thus,

ANOVA on rating scores did not reveal differences across female (left panel) and male (right
panel) genotypic groups, (Figure 3). (Female: Effect of Genotype F (2,21) = 0.143, p=0.868;
Effect of Time F (12,252) = 2.034, p=0.061; Effect of Time X Genotype F (24,252) = 1.435,
p=0.153). (Male: Effect of Genotype F (2,32) = 0.895, p=0.419; Effect of Time F (12,384) =
6.643, p=0.000; Effect of Time X Genotype F (24,384) = 0.478, p=0.930).

Combined stimulation of D1 and D2 receptors elicited pronounced stereotypy, regardless
of gender or genotype. However, gender specific significant effects of genotype were observed
(Figure 4).

Particularly, there were no differences among female genotypic groups in the

stereotypic response (left panel).

However, genotype differences were found in the male

response (right panel); specifically, male KO and Het showed higher stereotypy than male WT
(KO vs. WT, Fischer LSD post hoc test, p=0.012; Het vs. WT, Fischer LSD post hoc test,
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p=0.010), but there were no difference between male KO and Het. (Female: Effect of Genotype
F (2,21) = 0.743, p=0.488; Effect of Time F (12,252) = 36.510, p=0.000; Effect of Time X
Genotype F (24,252) = 0.737, p=0.658). (Male: Effect of Genotype F (2,32) = 4.923, p=0.014;
Effect of Time F (12,384) = 60.926, p=0.000; Effect of Time X Genotype F (24,384) = 0.772,
p=0.634).

Furthermore, it was also discovered differences in male but not female, in the stereotypic
response to D2 agonism (Figure 5). More specifically, there were no differences among female
genotypic groups in the stereotypic response (left panel). Nevertheless, it was found genotype
differences in the male response to D2 agonism (right panel). In particular, male KO showed
higher stereotypy than male WT and Het (KO vs. WT, Fischer LSD post hoc test, p=0.039; KO
vs. Het, Fischer LSD post hoc test, p=0.016), but there were no differences between male WT
and Het. (Female: Effect of Genotype F (2,21) = 1.377, p=0.274; Effect of Time F (12,252) =
62.968, p=0.000; Effect of Time X Genotype F (24,252) = 2.134, p=0.056). (Male: Effect of
Genotype F (2,32) = 3.685, p=0.036; Effect of Time F (12,384) = 102.583, p=0.000; Effect of
Time X Genotype F (24,384) = 4.497, p=0.000).

It was also discovered genotype differences in both male and female mice in the
behavioral response to D1 agonism. However, the scores did not approach what would be
considered stereotypy (Figure 6).

Female WT mice (left panel) displayed higher scores

compared to female KO and Het, (which do not differ). (KO vs. WT, Fischer LSD post hoc test,
p=0.000; WT vs. Het, Fischer LSD post hoc test, p=0.000). Similarly, male WT mice (right
panel) displayed higher rating scale scores compared to male KO and Het, (which do not differ).
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(KO vs. WT, Fischer LSD post hoc test, p=0.000; WT vs. Het, Fischer LSD post hoc test,
p=0.000). (Female: Effect of Genotype F (2,21) = 13.807, p=0.000; Effect of Time F (12,252) =
10.130, p=0.000; Effect of Time X Genotype F (24,252) = 0.785, p=0.665). (Male: Effect of
Genotype F (2,32) = 11.848, p=0.000; Effect of Time F (12,384) = 10.258, p=0.000; Effect of
Time X Genotype F (24,384) = 1.645, p=0.082).

With respect to possible variations in female mice due to the state of estrous cycle, we
did not take vaginal smears on each test day, as was done during open field testing. Our
rationale was that, in contrast to unstimulated locomotor activity, any effects of estrous variation
would be masked by the high dose of drugs used in assessing stereotyped behavior. To test this
assumption, we performed a preliminary experiment before testing the genetically engineered
mice. Stage of estrous cycle was determined in a group of female Swiss Webster mice. There
were no differences in stereotypy response across estrous cycle under basal conditions (saline, F
(3,40) = 0.613, p=0.611) and maximal dopamine stimulation (apomorphine, F (3,40) = 0.171,
p=0.916). This agrees with previous studies that support the absence of estrous cycle differences
in the stereotypy response under apomorphine conditions.

Thus, with respect to stereotypy it was found gender differences in the responses. Under
D1/D2 agonism condition, male KO and Het mice displayed significantly higher stereotypy than
male WT mice; however, there were found no differences among female groups. Moreover,
under D2 agonism condition, male KO mice showed significantly higher stereotypy than male
WT and Het mice; nevertheless, there were no significant differences among female groups.
Furthermore, under D1 agonism condition, WT mice showed higher levels of normal activity (but
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not stereotypy) compared to Het and KO mice (this was found for both genders). Finally, there
were no significant differences among KO, WT and Het groups, under basal levels of
dopaminergic stimulation (saline condition), for both genders.
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Table 3. Effects of Genotype on Locomotion

Description

Gender

Across days

n (Sample)

F value

P value

f

26

1.424

0.218

Across days

m

32

1.098

0.370

Across time

f

26

0.687

0.678

Across time

m

32

2.088

0.056
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Figure 1. Profile of anxiety behavior in female wild type,
knockout and heterozygous mice
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Figure 1. Profile of anxiety behavior in female wild type, knockout and heterozygous mice. Every bar represents
the mean time spent in the periphery of the open field (+ SE). The total amount of time for screening the behavior
per day was 30 minutes (1,800 sec). The higher the numeric value, the higher is the level of anxiety. There was a
significant effect of Genotype (F (2, 23) = 4.754, p = 0.019). Knockout showed significant higher anxiety compared
to wild type; wild type and heterozygous did not differed. There was not significant Day effect nor Day X Genotype
interaction (F (2, 23) = 0.273, p =0.763). Vertical lines depict standard errors of the means (+ SE). Wild type (n =
7), knockout (n = 9) and heterozygous (n = 8).
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Figure 2. Profile of anxiety behavior in male wild type, knockout
and heterozygous mice
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Figure 2. Profile of anxiety behavior in male wild type, knockout and heterozygous mice. Every bar represents the
mean time spent in the periphery of the open field (+ SE). The total amount of time for screening the behavior per
day was 30 minutes (1,800 sec). The higher the numeric value, the higher is the level of anxiety. There was not
significant effect of Genotype (F (2, 29) = 0.618, p = 0.546). There was not significant Day effect nor Day X
Genotype interaction (F (2, 29) = 0.420, p =0.661). Vertical lines depict standard errors of the means (+ SE). Wild
type (n = 11), knockout (n = 9) and heterozygous (n = 12).
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Figure 3. Profile of stereotypy behavior in wild type, knockout
and heterozygous mice - Saline condition
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Figure 3. Profile of stereotypy behavior in wild type, knockout and heterozygous mice – Saline condition. Behavior
was observed every 5 minutes for 30 seconds during 60 minutes following the second (agonist) injection, which in
this graph was saline. Each bar of the graph represents the average level of stereotypy behavior during 60 minutes.
Vertical lines depict standard errors of the means (+ SE). For female (left panel), no significant differences were
found among the groups; wild type (n = 7), knockout (n = 9) and heterozygous (n = 8). For male (right panel), no
significant differences were found among the groups; wild type (n = 12), knockout (n = 11) and heterozygous (n =
12).
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Figure 4. Profile of stereotypy behavior in wild type, knockout
and heterozygous mice - D1/D2 agonism condition
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Figure 4. Profile of stereotypy behavior in wild type, knockout and heterozygous mice – D1/D2 agonism condition.
Behavior was observed every 5 minutes for 30 seconds during 60 minutes following the second (agonist) injection,
which in this graph was apomorphine. Each bar of the graph represents the average level of stereotypy behavior
during 60 minutes. Vertical lines depict standard errors of the means (+ SE). For female (left panel), no significant
differences were found among the groups; wild type (n = 7), knockout (n = 9) and heterozygous (n = 8). For male
(right panel), there was a significant effect of Genotype; both knockout and heterozygous mice (which did not differ
from each other) showed significant higher stereotypy scores relative to wild type mice; wild type (n = 12),
knockout (n = 11) and heterozygous (n = 12).
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Figure 5. Profile of stereotypy behavior in wild type, knockout
and heterozygous mice - D2 agonism condition
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Figure 5. Profile of stereotypy behavior in wild type, knockout and heterozygous mice - D2 agonism condition.
Behavior was observed every 5 minutes for 30 seconds during 60 minutes following the second (agonist) injection,
which in this graph was apomorphine (pre-treatment was a D1 antagonist). Each bar of the graph represents the
average level of stereotypy behavior during 60 minutes. Vertical lines depict standard errors of the means (+ SE).
For female (left panel), no significant differences were found among the groups; wild type (n = 7), knockout (n = 9)
and heterozygous (n = 8). For male (right panel), there was a significant effect of Genotype. Knockout mice
showed significantly higher stereotypy scores relative to heterozygous and wild type mice. Also, there was Time X
Genotype interaction; Wild type (n = 12), knockout (n = 11) and heterozygous (n = 12).
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Figure 6. Profile of stereotypy behavior in wild type, knockout
and heterozygous mice - D1 agonism condition
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Figure 6. Profile of stereotypy behavior in wild type, knockout and heterozygous mice – D1 agonism condition.
Behavior was observed every 5 minutes for 30 seconds during 60 minutes following the second (agonist) injection,
which in this graph was apomorphine (pre-treatment was a D2 antagonist). Each bar of the graph represents the
average level of stereotypy behavior during 60 minutes. Vertical lines depict standard errors of the means (+ SE).
For female (left panel), there was a significant effect of Genotype; wild type mice showed significantly higher
scores than knockout or heterozygous mice; wild type (n = 7), knockout (n = 9) and heterozygous (n = 8). For male
(right panel), there was a significant effect of Genotype. Wild type mice showed significant higher rating scale
scores relative to knockout and heterozygous mice; wild type (n = 12); knockout (n = 11) and heterozygous (n = 12).
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Chapter 4
Discussion

The present study was undertaken to address the general question of whether the recently
discovered gene rhes, which is highly expressed in brain regions innervated by DA, exerts a
causal influence on behaviors whose expression is mediated by this important neurotransmitter.
The evidence obtained supports the hypothesis that drug-elicited behaviors, but not spontaneous
behaviors, are affected by the level of Rhes protein in the brains of genetically engineered mice.
In addition, we found that several of these effects were gender-specific.

The first hypothesis, that there would be an inverse relationship between the levels of
Rhes protein in the basal ganglia and spontaneous locomotor and exploratory activity, was not
supported by the data. With respect to the total amount of activity in the open field there were no
effects of genotype in either male or female mice.

However, with respect to anxiety (as

measured by the relative amount of time spent in the periphery vs. the center of the open field in
the first two sessions), the results show gender-specific effects of Rhes protein level. Female
mice incapable of synthesizing Rhes protein (i.e., KO mice) showed significantly lower levels of
anxiety than WT or Het mice. By contrast, no effect of genotype was observed in male mice.
These findings do not agree with the previous results of Spano et al. (2004): following a nonsignificant main effect of genotype (p = 0.08), post hoc tests revealed that KO mice showed
significantly less behavior in the first 5 minutes of the open field test, an effect that we did not
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observed. It should be noted that those authors used combined data from male and female mice;
however, our gender-specific effects cannot account for this discrepancy. Moreover, the present
results in anxiety also differ from those obtained by Spano et al., (2004). Spano et al., (2004)
found higher level of anxiety in the female KO group. This discrepancy could be explained by
differences in sampling (Spano used only n = 5 per genotype), methodology (Spano used the
elevated plus maze test rather than the open field), and habituation and handling of the mice (in
the present study, mice were habituated but this is not described in Spano’s report).

The major finding of the current research project is that evidence was obtained to
partially support the second hypothesis, that there would be a significant effect of genotype on
the responses of mice to drug stimulation of D1 and D2 receptors. However, one aspect of that
hypothesis, that KO mice would show a breakdown in D1/D2 synergism, was not supported.

First, KO and Het males displayed significantly higher stereotyped motor behavior in
response to D2 agonism alone compared to WT mice. This increase was restricted to the initial
temporal intervals which is consistently related to D1-independent (i.e., non-synergistic) D2
effects. Second, the prediction that stereotyped motor behavior elicited by combined D1/D2
agonism would be significantly higher compared to wild type, and that heterozygous mice would
show a response intermediate between KO and WT mice, was partially confirmed. In effect,
male KO mice showed significant higher levels of stereotypy compared to male wild type; male
heterozygous mice showed significantly higher stereotypic response than did wild type mice, to a
level that was similar to male knockout mice, (no significant difference) rather than intermediate.
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In general, the decrease in Rhes protein levels (knockout and heterozygous) is associated to a
higher stereotypic response due to D2 receptors supersensitivity, as initially speculated.

Contrary to the predictions of the second hypothesis, neither male nor female knockout or
heterozygous mice showed higher stereotypy scores than did wild type mice following selective
stimulation of D1 receptors. All genotypes displayed the typically very low scores on our rating
scale under this condition. Despite these low scores (which are not sufficiently high to be
regarded as stereotyped motor behavior), an unexpected effect was evident: KO and Het mice
(male and female) showed significantly lower scores than did WT mice. To account for the role
of endogenous DA when testing for the effects of selective D1 or D2 receptor stimulation, it is
necessary to block the heterotypic (in this case, a D2 antagonist) receptor with a selective
antagonist. In normal animals with intact D1/D2 synergism (including WT mice), D1 or D2
antagonists induce catalepsy. This occurred in the present study as is evident by comparing the
range of scores in Figure 6 with those in Figure 3, in which no antagonist was given. The
significant effect of genotype may therefore indicate that KO and Het mice are more sensitive
than WT to the cataleptic effects of a D2 antagonist.

The major interpretation of these findings is that male mice with impaired synthesis of
Rhes protein (either partial or complete) show increased sensitivity to agonist stimulation of D2
receptors, regardless of activity at the D1 receptor. The present findings agree with previous
studies demonstrating that changes in rhes mRNA are consistently associated with changes in the
sensitivity of dopamine receptors in the brain (Harrison et al., 2006). Specifically, those authors
found that all treatments that increase D2 receptor sensitivity decrease rhes mRNA (and Rhes
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protein; L.M. Harrison, unpublished results) whereas treatments that do not increase sensitivity
do not alter rhes mRNA.

The present study contributes significantly to this field in that these experiments permit
conclusions regarding a causal relationship between Rhes levels and behavior to be made. In the
light of recent evidence, it is interesting that the effects of decreased Rhes were restricted to D2
receptors.

The intercellular signals initiated by DA receptor agonism are transduced into

intracellular signals via G proteins. Rhes shows strong homology with another protein (AGS1)
that is known to interact with G proteins, and it is believed that this is the mechanism by which
Rhes exerts its influence on DA receptor sensitivity. Harrison (unpublished observations) has
found that Rhes specifically interacts with G protein subtypes (Gi) that couple with D2 receptors,
but not with subtypes (Gs) that couple with D1 receptors.

Despite the significant effects of Rhes levels on D2 receptor sensitivity, a major
hypothesis of the present study was not confirmed. There was no evidence that decreased Rhes
protein resulted in a breakdown in D1/D2 synergism. Such a breakdown would have been
evidenced by the expression of full stereotypy following selective stimulation of D1 or D2
receptors alone. Given the presence of a positive control (i.e., combined stimulation of D1 and
D2 receptors) these results lead to an important conclusion regarding the mechanism underlying
the breakdown of D1/D2 synergism: the cause of the breakdown observed in previous studies is
unlikely to be simply the reduced expression of Rhes. (However, see the discussion below on
limitations of the mouse KO model.)
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A very interesting and novel finding of this study is that the effects of Rhes were genderspecific, occurring in male mice but not female (although its effect in female when D2 receptors
alone were stimulated was very nearly significant: p = .056). None of the previous work
showing a correlation between rhes mRNA and receptor sensitivity has included female animals.
It would be very interesting to test males and females together to see whether females show
changes in rhes mRNA following treatments that have previously shown to decrease rhes in
males. If it were shown in several paradigms that the modulation of DA-mediated behaviors by
rhes were consistently restricted to males, it would be useful to understand the underlying cause
of this intriguing sex difference.

The gender differences observed here suggest possible hormonal influences in the effects
of Rhes on DA-mediated behaviors. Sex hormones can act in two distinct ways. Activational
effects of sex hormones are the widely known actions whereby circulating hormones induce
behavioral, neural or endocrine effects that are temporary and dependent on the presence of the
hormone. Organizational effects refer to the profound, permanent, developmental effects of low
doses of hormones during a critical period of development; these effects are manifested in
adulthood even in the absence of hormone.

Could circulating estrogens (i.e., activational effects) in female rhes KO and Het mice
account for sex differences observed in the current study? A strong argument against this is the
finding that the stage of estrous cycle had no effect on the behaviors measured. Mice in the
diestrous phase have very low levels of estrogens, similar to male mice, yet their behavior was
significantly different from that of male mice. Testosterone, on the other hand, is a more viable
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candidate to explain the gender differences. That is, testosterone, present in males but not
females, may be required for Rhes to exert its influence on DA receptor sensitivity. These
hypotheses can be readily tested.

With respect to organizational effects, circulating androgens in utero and immediately
postnatally in rodents virtually determine whether a “male” or “female” brain will develop,
regardless of sex karyotype (i.e., XX or XY). Such effects would be independent of circulating
hormone levels at the time of testing. As with the activational effects, this hypothesis can be
readily tested.

As in all experiments using mice in which a gene is knocked-out from the single-cell
stage, interpretations of the present results require caution. This model of mutant mice has the
limitation of potential genetic compensatory responses that could lead to anatomical and
physiological compensations during development. Subsequent studies could explore the present
findings with a knockout model in which the knocking out condition is restricted in time, for
example, adulthood (temporal conditional knockout).

The findings here may have important implications for the treatment of psychiatric and
neurological disorders.

Since decreased Rhes was shown to increase D2 sensitivity, these

findings point to novel drug targets in the treatment of disorders in which D2 supersensitivity is
involved. For example, the major hypothesis of schizophrenia is that psychosis is caused by
enhanced sensitivity of D2 receptors to endogenous DA. In the complex signaling pathway of
GPCRs there are factors that inhibit the action of proteins like Rhes (e.g., GEFs; guanine
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nucleotide exchange factors). Based on the present findings, such GEFs are potential novel drug
targets in the treatment of D2 sensitivity-related disorders. For example, a drug that interferes
with the activity of one or more GEFs (it is far easier to synthesize novel drugs that interfere with
a normal process than to synthesize one that facilitates such a process) would (by disinhibition)
increase the activity of Rhes, thereby restoring D2 sensitivity to normal levels.

Interestingly, decreased Rhes itself may be a contributing factor in the manifestation of
psychotic symptoms. The human rhes gene has been localized to Ch 22q13.1, a “hot spot”
consistently identified by linkage analysis as being associated with schizophrenia. It might be
important to examine post mortem brain tissue from patients with schizophrenia with respect to
levels of rhes mRNA or Rhes protein. Even in the absence of differences in actual Rhes levels,
patients with schizophrenia may possess a variant allele that encodes for a less efficient Rhes
protein, rendering their D2 receptors supersensitive.

In addition, patients in the advanced stages of Parkinson’s disease (PD) often must
discontinue the use of L-DOPA (the only effective treatment) because of rapid fluctuations
between debilitating dyskinesias and akinesia following drug treatment (the “on-off”
phenomenon), an effect believed to be due to the development of D2 supersensitivity. A drug
like one described above, might reduce this supersensitivity and prolong the amount of time that
L-DOPA can be used, effectively prolonging the life of the patient.

In conclusion, the present research shows that changes in Rhes protein levels do not
affect basic levels of locomotion in the open field in both genders. However, decrease in the
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level of Rhes protein seems to have an anxiolytic effect in female, but not male mice. In
addition, the present work supports the role of Rhes protein in the modulation of the dopamine
D2 (but not D1) receptor supersensitivity in male, but not female mice. However, there was no
evidence that variation in the levels of Rhes could account for the breakdown in synergism
previously observed following treatments that concomitantly decreased Rhes.
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